Dublin, July 21, 2020 (GLOBE NEWSWIRE) -- The "Europe Bladder Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. The report provides ...
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast ...
Oncology Media Relations Oncology_media_relations@its.jnj.com Investor contact: Jess Margevich investor-relations@its.jnj.com ...
Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results